비교리스트

 카트 문의
시장보고서
상품코드
1514005

세계의 급성 관상동맥 증후군 시장

Acute Coronary Syndrome
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 182 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 급성 관상동맥 증후군 시장은 2030년까지 176억 달러에 이를 것으로 예상

2023년에 87억 달러로 평가된 세계의 급성 관상동맥 증후군 시장은 2030년에는 176억 달러에 이를 전망이며, 분석 기간 2023년부터 2030년까지 CAGR은 10.5%로 성장할 것으로 예측됩니다.

미국 시장은 23억 달러, 중국은 CAGR 16.4%로 성장 예측

미국의 급성 관상동맥 증후군 시장은 2023년 23억 달러로 평가되었습니다. 세계 2위 경제대국인 중국은 2030년까지 45억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023년부터 2030년까지 CAGR은 16.4%로 전망됩니다. 다른 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 4.5%와 10.3%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 6.4%로 성장할 것으로 예측됩니다.

급성 관상동맥 증후군-주요 동향 및 촉진요인

급성 관상동맥 증후군(ACS)은 심근으로의 혈류가 갑자기 감소함에 따라 발생하는 심장 관련 문제의 스펙트럼을 포함하는 심각한 상태입니다. 이 지역은 불안정한 협심증, 비 ST 상승 심근 경색(NSTEMI) 및 ST 상승 심근 경색(STEMI)를 포함합니다. ACS의 주요 원인은 관상 동맥 내의 죽상 동맥 경화반의 파열 또는 침식이며, 혈전(혈괴)이 형성되어 동맥의 일부 또는 전부를 막습니다. 이 폐색은 심근으로의 산소 공급을 감소시키고 허혈을 유발하며 치료되지 않은 경우 심근 경색(심장 발작)으로 이어집니다. 환자는 보통 흉통과 불쾌감과 같은 증상을 나타내며, 그 증상은 팔, 목, 턱, 등에까지 퍼질 수 있으며, 호흡 곤란, 발한, 메스꺼움, 현기증 등을 동반할 수 있습니다. 조기 및 정확한 진단이 중요하며 일반적으로 임상 평가, 심전도(ECG), 트로포닌과 같은 심장 바이오 마커의 혈액 검사, 심 초음파 검사 및 관상 동맥 조영술과 같은 이미지 검사를 결합하여 달성됩니다.

ACS의 치료 전략은 혈류를 신속하게 회복시키고 심근 손상을 최소화하고 추가 합병증을 예방하는 것을 목표로 합니다. 약리학적 개입으로는 항혈소판약(아스피린이나 P2Y12 억제제 등), 항응고제(헤파린 등), β차단제, 질산약, 스타틴 등이 있으며, 이들은 정리하여 플라크의 안정화, 혈전 형성 억제, 증상의 관리, 심혈관 사건의 예방에 도움이 됩니다. 심한 동맥 폐색과 흉통이 계속되는 환자는 경피적 관상동맥 인터벤션(PCI) 및 관상동맥 우회술(CABG)과 같은 인터벤션 치료를 받습니다. PCI는 종종 약물 용출 스텐트의 유치를 수반하지만, 재협착(동맥의 재협착)을 감소시키는 효과가 있기 때문에 ACS 관리의 요점이 되고 있습니다. 이러한 인터벤션 절차의 진보는 새로운 항혈소판제와 항응고제의 개발과 함께 ACS 환자의 생존과 결과를 현저하게 개선했습니다. 급성기 치료 후 관리에는 생활 습관 개선, 심장 재활, 사건 재발 위험을 줄이기 위한 장기 복약 준수 등이 포함됩니다.

ACS 시장의 성장은 여러 요인에 의해 야기됩니다. 첫째, 심혈관 질환의 유병률 증가가 주요 촉진요인이며, 그 주요 원인은 인구의 고령화와 비만, 운동 부족, 식생활의 혼란, 흡연, 당뇨병 및 고혈압의 이환율의 상승과 같은 생활습관과 관련된 위험인자입니다. 둘째, 진단 기술의 발전으로 ACS의 조기적이고 정확한 발견이 가능해지고 있습니다. 고감도 심장 바이오마커와 심장 MRI 및 CT 혈관 조영술과 같은 고급 영상 진단 기술은 적시에 정확한 진단을 가능하게 하며, 이는 효과적인 개입에 필수적입니다. 셋째, 새로운 치료제와 고급 인터벤션 절차의 지속적인 개척은 치료 옵션을 확대하고 환자 결과를 개선하고 시장 성장을 가속합니다. 또한 심혈관계의 건강에 대한 인식과 교육이 증가하고 있으며, 더 많은 사람들이 증상의 조기발현시 의료기관을 진찰하게 되어 ACS 관련 헬스케어 서비스에 대한 수요가 증가하고 있습니다. 심혈관 치료 인프라와 연구 강화에 중점을 둔 정부의 이니셔티브와 자금 지원도 시장을 강화하고 있습니다. 마지막으로, 원격 의료와 디지털 건강 솔루션의 통합은 환자 모니터링과 후속 관리를 강화하고, ACS를 더 잘 관리할 수 있게 하고, 전체 시장 확대에 기여합니다. 이러한 디지털 진보는 환자의 원격 모니터링, 시기 적절한 의료 개입, 치료 요법의 어드히어런스 향상을 가능하게 하여 ACS 시장의 성장을 더욱 촉진하고 있습니다.

조사 대상 기업 예(총 62건)

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향 및 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

AJY 24.07.24

Global Acute Coronary Syndrome Market to Reach US$17.6 Billion by 2030

The global market for Acute Coronary Syndrome estimated at US$8.7 Billion in the year 2023, is expected to reach US$17.6 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 16.4% CAGR

The Acute Coronary Syndrome market in the U.S. is estimated at US$2.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 16.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Acute Coronary Syndrome - Key Trends and Drivers

Acute Coronary Syndrome (ACS) is a critical condition that encompasses a spectrum of heart-related issues arising from the sudden reduction of blood flow to the heart muscle. This spectrum includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). The primary underlying cause of ACS is the rupture or erosion of atherosclerotic plaques within the coronary arteries, leading to thrombus (blood clot) formation that partially or fully obstructs the artery. This obstruction compromises oxygen delivery to the heart muscle, causing ischemia and, if untreated, can lead to myocardial infarction (heart attack). Patients typically present with symptoms such as chest pain or discomfort, which may radiate to the arm, neck, jaw, or back, as well as shortness of breath, sweating, nausea, and dizziness. Early and accurate diagnosis is crucial and is typically achieved through a combination of clinical evaluation, electrocardiograms (ECGs), blood tests for cardiac biomarkers like troponins, and imaging studies such as echocardiography or coronary angiography.

Treatment strategies for ACS are aimed at quickly restoring blood flow, minimizing heart muscle damage, and preventing further complications. Pharmacological interventions include antiplatelet agents (e.g., aspirin and P2Y12 inhibitors), anticoagulants (e.g., heparin), beta-blockers, nitrates, and statins, which collectively help in stabilizing the plaque, reducing clot formation, managing symptoms, and preventing further cardiovascular events. For patients with severe artery blockage or ongoing chest pain, interventional procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are employed. PCI, which often involves the placement of drug-eluting stents, has become a cornerstone in ACS management due to its efficacy in reducing restenosis (re-narrowing of the artery). Advances in these interventional techniques, along with the development of new antiplatelet and anticoagulant medications, have significantly improved survival rates and outcomes for ACS patients. Post-acute management includes lifestyle modifications, cardiac rehabilitation, and long-term medication adherence to mitigate the risk of recurrent events.

The growth in the ACS market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases is a major driver, largely due to aging populations and lifestyle-related risk factors such as obesity, physical inactivity, poor diet, smoking, and the rising incidence of diabetes and hypertension. Secondly, advancements in diagnostic technologies are enabling earlier and more precise detection of ACS. High-sensitivity cardiac biomarkers and advanced imaging techniques like cardiac MRI and CT angiography allow for timely and accurate diagnosis, which is critical for effective intervention. Thirdly, the continuous development of novel therapeutic agents and sophisticated interventional procedures is expanding the arsenal of treatment options, thereby improving patient outcomes and driving market growth. Additionally, there is a growing awareness and education about cardiovascular health, which is encouraging more individuals to seek medical attention at the early onset of symptoms, thus increasing the demand for ACS-related healthcare services. Government initiatives and funding focused on enhancing cardiovascular care infrastructure and research are also bolstering the market. Lastly, the integration of telemedicine and digital health solutions is enhancing patient monitoring and follow-up care, enabling better management of ACS and contributing to overall market expansion. These digital advancements allow for remote patient monitoring, timely medical interventions, and improved adherence to treatment regimens, further driving the growth of the ACS market.

Select Competitors (Total 62 Featured) -

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Acute Coronary Syndrome - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
    • Aging Population Throws the Spotlight on Growing Incidence of ACS
    • Rising Rates of Obesity and Diabetes Propel Growth in ACS Cases
    • Advances in Diagnostic Technologies Spur Adoption of Early Detection Methods
    • Development of High-Sensitivity Cardiac Biomarkers Strengthens Business Case for Precise Diagnosis
    • Innovations in Imaging Techniques Improve ACS Detection
    • Enhanced Antiplatelet and Anticoagulant Therapies Generate Demand for Advanced Treatment Options
    • Integration of Drug-Eluting Stents in PCI Procedures Drives Adoption of Interventional Treatments
    • Increased Awareness and Education on Heart Health Propel Growth in Preventive Measures
    • Advances in Telemedicine and Digital Health Solutions Aid Better ACS Management
    • Expansion of Cardiac Rehabilitation Programs Drives Demand for Post-Treatment Services
    • Increasing Utilization of Artificial Intelligence in ACS Diagnosis and Treatment
    • Focus on Reducing Hospital Readmission Rates Strengthens Business Case for Effective ACS Management
    • Adoption of Mobile Health Applications for Heart Monitoring Drives Market Growth
    • Expansion of Healthcare Services in Emerging Markets Expands Addressable Market for ACS Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Coronary Syndrome Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제